






RETINAL VASCULAR DISEASES


Prof. Dr. Şengül Özdek
www.sengulozdek.com



- 
-
- Retinal Vein Occlusions
 - Retinal Artery Occlusions
 - Diabetic Retinopathy
 - Retinal Vasculitis (Behçet, Eales etc)
 - Retinal telangiectasis (Coats disease)
 - ROP
 - Age Related Macular Degeneration

Histology of retina






Retinal Vasculature

inner layer → **central retinal vascular system**


outer layer → **choroid (ciliary vascular system)**

macula lutea → **choriocapillaries!**




Retinal Barriers

- **Inner barrier (blood–retina barrier):** retinal capillary endothelium
- **Outer barrier (choroid-retina barrier):** zonula occludens between the **RPE**, RPE- Bruch's membrane- choriocapillaries complex




Symptoms

- **Visual impairment**
- **Metamorphopsia**
- **Macropsia / Micropsia**



Signs

- Edema
- Hemorrhage
- Exudation
- Neovascularization



Signs

- **Intracellular edema**

Retinal artery occlusion:
ischemia leads to edema
of bipolar cell, ganglion and RNFL


- **Extracellular edema**

Capillary endothelium injury and
exudation


- **Cystoid macular edema**

Henle's fibers are radially located;
This pooling forms a flower-petal pattern.


Retinal Edema



**Intracellular edema
CRAO**



**Extracellular edema
CRVO**



Exudates

Hard exudate


**Leakage of capillary → absorb →
deposition of lipid in outer plexiform layer**

Soft exudate


**“Cotton-wool spot”
Precapillary arteriole occlusion →
axoplasmic transport blocked → organelles stack**



Cotton-wool spot



Hard exudate (Diabetic retinopathy)



Hemorrhage

Subretinal hemorrhage

Located in under retina,
mostly the source is choroid

Retinal hemorrhage


Located in nerve fiber layer
Line, strip, flame-like, bright
red


Preretinal hemorrhage




Crescent-shaped hematocoele
with transverse section


Vitreous hemorrhage

Profuse preretinal
hemorrhage into the vitreous
or hemorrhage of retinal
neovascularization











Neovascularization




Retinal ischemia
VEGF
neovascularization




Blood vessel change

- Atherosclerosis, stenosis, occlusion
- Tortuous vein, dilated vein, bead-like change



A-v cross sign





Vessel white sheath



Microaneurysm


CENTRAL RETINAL ARTERY OCCLUSION






Causes



- Atherosclerosis-related thrombus
- Emboli:
 - Carotid: atheroma plaques
 - Cardiac: (calcific valvular or mural thrombosis in atrial fibrillation)
 - Aortic
- Inflammatory: Giant cell arteritis, SLE
- Trauma,
- Thrombophilic disorders:




Signs-Symptoms


- Sudden painless visual loss
- Mostly Counting Fingers level
- Examination: RAPD!
 - (Direct pupil reflex↓)
- Fundus!












FFA










Treatment


- Vasodilator: antispasm or pushing thrombus to the smaller branch
- Reducing IOP:
 - Massage
 - anterior chamber paracentesis
 - CAI, Mannitol 20%
- O2 inhalation: mixture of 95% oxygen & 5% carbon dioxide
- Fibrolytics: for patients suspect of thrombosis: urokinase, tPA





Prognosis

- Poor
- Treatment?
 - Only within first few hours

CENTRAL/BRANCH RETINAL VEIN OCCLUSIONS







Risk Factors


- CRVO





- Systemic Hypertension
- Cardiovascular Disease
- Diabetes Mellitus
- POAG


- BRVO

- Systemic Hypertension
- Cardiovascular Disease
- Glaucoma
- Increased Body Mass Index at 20 yrs old
- Hypercoaguable States


Nonischemic vs Ischemic








CRVO
Nonischemic



CRVO
ischemic



Treatment


- Antitrombotic agents?
- Intravascular thrombolysis?
- IV steroids
 - Triamcinolone
 - Dexamethasone implants
- IV Anti-VEGFs
 - Bevacizumab
 - Ranibizumab


Ischemic CRVO

- Neovascularization: Iris&angle
 - Neovascular Glaucoma
- Panretinal Laser Photocoagulation: PRP



BRANCH RETINAL VEIN OCCLUSION (BRVO)






Treatment

- Grid Laser
- Laser PC to ischemic areas if NVE (+)
- IV steroids
 - Triamcinolone
 - Dexamethasone implants
- IV Anti-VEGFs
 - Bevacizumab
 - Ranibizumab





Prognosis


- CRVO


- Approximately 30% ischemic (10 DD on FA)
- **NVG 40% to 60%** of these eyes vs 5% Nonischemic
- <10% developed retinal neovascularization
- CVOS – 83% of undetermined developed ischemia or NVI

- BRVO


- 1/3 to 1/2 recover VA of 20/40 or better w/o therapy
- 50% Ischemic (5 DD) of which **40% develop neovascularization; 60% of these develop VH**
- NVI Rare; 1%


BRVO-Collaterals





COATS DISEASE


- 
-
- Unilateral gradual loss of vision
 - Predominantly in young males (1st decade)
 - Peak age of onset: 6-8 years
 - RD, NVG, Cataract, **Leukocoria**,
 - DD: Retinoblastoma






Retinal Findings


- Aneurismal and telangiectatic vessels
- Breakdown of blood retinal barrier
- Leakage of blood, serum, cholesterol to retina
- Exudative RD....Loss of retinal red reflex
- Loss of retinal capillary
- Ischemia.... NV....NVG...


Loss of retinal red reflex







Medscape













a

b







NOTICE!

DIFFERENTIATE
FROM
RETINOBLASTOMA!

Other DD:
ROP, FEVR






Treatment



- Laser PC
- Cryotherapy
- IV-Anti-VEGF
- RD: Surgery: VRS
- Enucleation


PREMATURE RETINOPATHY



Patogenez

- Normal retinal vaskülerizasyon:
 - Nazal : 36 hf
 - Temporal: 40.hf.
- İntrauterin retinal vaskülerizasyon:
rölatif hipoksik ortam
- Prematürite: avasküler retina...
- O2 ted.....**VEGF down regülasyonu**
- Vaskülerizasyon duraklar.... Avasküler alandan
VEGF.... **VEGF up regülasyonu... ROP**







Uluslararası ROP sınıflandırması (ICROP)

■ Parametreler


1. Zon (1,2,3)
2. Evre (1-5)
3. Yaygınlık (saat kadranı)
4. "Artı hastalık" varlığı





ICROP



Hastalığın yaygınlığı




Evre 1: Demarkasyon hattı









Evre 2






Evre 2-3







Evre III
ROP
Hafif-Orta-
Şiddetli

Evre 4





Evre 5





Artı (plus) hastalık

- Arka kutupta retinal vasküler dilatasyon ve tortuosite artışı
- Aktif progresyon belirtisi
- Çok hızlı ilerleme!....



Zon 1, Artı hastalık (APROP)





Tedavi endikasyonu (ICROP-revisited-2005)

- zon I ROP: artı hastalık
 - (evre, yaygınlık önemsiz)
- zon I ROP: evre 3 / artı hastalık (-)
- zon II: evre 2 veya 3 / artı hastalık

International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited.

Arch Ophthalmol. 2005;123:991–999

AP-ROP: Aggressive Posterior ROP


(AP-ROP): ÇDDAP daha sık




- Posterior yerleşim (Zone 1)
- (+) hastalık
- Evre önemsiz ve sınır genellikle belirsiz

72 saatte tedavi!...


Tedavi öncesi ve sonrası




lazer



Anti-
VEGF



TARAMA



Tarama

AAP-AAO (2006 ROP Politikası)

- ≤ 32 hf ve < 1500 gr: Rutin tarama
- 1500-2000 gr
- > 32 hf
 - Klinik gidiş stabil değilse
 - Kardiopulmoner destek ihtiyacı (+)

Retina muayenesi

İlk muayene: Optimal zaman

****PP 4. hf veya PM 31. hf (hangisi daha geç ise)**




Eşik veya eşik öncesi yüksek risk: **35-37hf**






Krio - Lazer







E.T. (108132)
DOB: 6/14/2005
Imaged on: 7/26/2005
Eye: OD
ROP
evre 3 plus




Zon 1 prematürite retinopatisinde tedavi sonuçları ve prognoz

- Lazer tedavisi: Anatomik başarı $>\%90$
- Cerrahi tedavi: Anatomik başarı $<\%50$


- Tök L, Urgancıoğlu B, Özdek Ş, ve ark. Zon 1 prematürite retinopatisinde tedavi sonuçları ve prognoz. MN Oftalmoloji, 2008; 15(2): 101-105.

Evre 4: Subtotal Retina dekolmanı

a) extrafoveal b) foveayı da içine alan RD




Stage 4A Retinopathy of Prematurity




Stage 4B Retinopathy of Prematurity


TEDAVİ: CERRAHİ

Çevresel Skleral Çökertme



Vitrektomi









Lens koruyucu vitrektomi



Evre 5: Total retina dekolmanı: Lökokori




Severe Stage 5 Retinopathy of Prematurity



Yeni tedaviler

- Anti VEGF ajanlar (intravitreal)
 - Bevacizumab (Avastin/Altuzan)
 - Ranibizumab? (Lucentis)

AGE RELATED MACULAR DEGENERATION




ARMD

DPV

WET

NEOVASCULAR




EARLY VS ADVANCED DISEASE

Risk Factors

- Age >55y
- Genetic predisposition:
Family history
- Cigarettes smoking
- HT






Signs&Symptoms


- Metamorphopsia
 - Central scotoma
 - Visual loss
-
- FUNDUS: Drusen, RPE atrophy

Drusen

Histopathology




Hard



- Small well-defined spots
- Usually innocuous



Soft





- Larger, ill-defined spots
- May enlarge and coalesce
- Increased risk of AMD

Diagnostic tests


- Fundus Fluorescein Angiography (FFA)
- Optic Coherence Tomography (OCT)





FFA




OCT




OCT in wet ARMD




OCT in Dry ARMD





Advanced atrophic ARMD





Management of Dry ARMD


- Regular follow-up
- Early visit if metamorphopsia develops
- Anti-oxidant Vitamin-Fish oil intake to decrease the risk for neovascular ARMD


Amsler Grid

As it might appear to someone with age-related macular degeneration.




Progression to wet type





Neovascular ARMD

- Rapidly progressive visual loss
- Progressing central scotoma if untreated
- Treatment:
 - IV-Anti-VEGF injections
 - PDT: rarely
 - Laser Photocoagulation?







Example of central vision loss



Treatment

- IV Pharmacotherapy
 - IV Anti-VEGF:
 - Ranibizumab
 - Bevacizumab
 - Aflibercept (VEGF trap eye)
- PDT: Rarely
- Laser Photocoagulation??



MARINA

■ LUCENTIS 0.5 mg (n=240)

---○--- Sham (n=238)


ANCHOR


■ LUCENTIS 0.5 mg (n=140)

---●--- Verteporfin PDT (n=143)

IV




Leaking
blood vessel






Response to Anti-VEGF

- %25-30: **VEGF Responder**: ilk 3 doz yeterli
- %65: **VEGF Bağımlı**
- %5-10: **VEGF Cevapsız**





■ VA:0.3.....VA:1.0


Treatment



Nonresponders-Hemorrhagic response










DIABETIC RETINOPATHY



DR-DMÖ











PDR-NV













Panretinal Laser Photocoagulation treatment

